- Home
- MLYS vs EOI Comparison
MLYS vs EOI Comparison
Compare MLYS & EOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MLYS | EOI |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 793.7M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | MLYS | EOI |
|---|---|---|
| Price | $36.99 | $19.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $46.40 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 83.6K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.19% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.24 | $14.36 |
| 52 Week High | $47.65 | $18.88 |
Technical Indicators
Market Signals| Indicator | MLYS | EOI |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 41.11 |
| Support Level | $35.77 | $19.47 |
| Resistance Level | $44.13 | $19.79 |
| Average True Range (ATR) | 1.93 | 0.22 |
| MACD | -0.64 | 0.04 |
| Stochastic Oscillator | 14.95 | 34.21 |
Price Performance
Historical ComparisonAbout MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation.